Camrelizumab
- Generic Name
- Camrelizumab
- Drug Type
- Biotech
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer
- Conditions
- Advanced Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2025-02-27
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT06849492
- Locations
- 🇨🇳
Fudan Cancer Hospital, Shanghai, Shanghai, China
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
- Conditions
- Adrenal Cortical CarcinomaAdrenal Cortical CancerAdrenal Cancer
- Interventions
- First Posted Date
- 2025-02-17
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 28
- Registration Number
- NCT06831175
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Carcinoma
- Interventions
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Zhejiang University
- Target Recruit Count
- 43
- Registration Number
- NCT06759090
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC
- Conditions
- Triple Negative Breast Cancer (TNBC)Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2024-12-12
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT06731153
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
First-line Treatment of Advanced/unresectable DDLPS
- Conditions
- Dedifferentiated LiposarcomaSoft Tissue Sarcoma (STS)
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 49
- Registration Number
- NCT06694324
- Locations
- 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Conditions
- Rare Tumour
- Interventions
- Drug: Other
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
- Conditions
- Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06693128
- Locations
- 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳Changhai Hospital, Shanghai, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, China
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
- Conditions
- Nasopharyngeal Cancinoma (NPC)
- Interventions
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 242
- Registration Number
- NCT06669611
- Locations
- 🇨🇳
SunYat-senU, Guangzhou, Guangdong, China
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06654297
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-03-26
- Target Recruit Count
- 60
- Registration Number
- NCT06632405
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.